NanoViricides: Big Things In a Small Package
During an interview with OneMedPlace, President and Chairman of NanoViricides (NNVC) Anil Diwan summed up the influenza treatment market in just a few words: It is like trying to hit a moving target.
news1
Cyto Wave Technologies CEO: First Device to Detect Circulating Tumor Cells In Vivo
Cyto Wave Technologies’ iV3 device can detect circulating tumor cells in real time via laser technology and potentially destroy cells. OneMedRadio spoke with Cyto Wave Technologies President and CEO George Yu about the favorable on-ramp to commercialization, clearing regulatory and reimbursement obstacles and the vast opportunity for in vivo CTC detection.
RELEASE: Mercator MedSystems Raises Additional $6.5 Million
Mercator MedSystems, Inc., a privately-held medical technology company reinventing the treatment of disease deep inside the body, today announced the closing of a $6.5 million Series B financing. The funding will be used to initiate sales of its Cricket™ and Bullfrog® Micro-Infusion devices in Europe, the United States and Australia.
Medical Services Companies Showing Strong Earnings
Healthcare has been one of the hottest sectors over the past year. This can be seen by looking at various ETFs such as iShares Dow Jones US Healthcare (IYH). This particular ETF has appreciated by approximately 35% over the past 52 weeks which is significantly higher than the 27% appreciation that the S&P Depository Receipts (SPY) has given investors. Now the healthcare sector is built up of many smaller industries and this article will focus on medical services companies which have produced strong quarterly results.
The 10 “Do’s and Don’t’s” When Networking at a Healthcare Conference
With OneMedForumNY 2013 just one month away (and a few healthcare conferences coming up), we thought it best to step away from our usual editorial functions and instead offer a ‘how to’ on enhancing your conference experience. Below, find 10 (actually, 11) tips to maximizing your conference networking. We’ve scattered in some special tricks, as well.
MAPPING THE B.R.A.I.N.
On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.
Bioinformatics Special Report, Part I: Where Does Biotechnology Data Come From?
Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.
ISTO Technologies CFO: No Other Company Can Grow Living Cartilage in a Lab Setting
ISTO Technologies has a unique pipeline that has demonstrated both clinical progress and market success. With one commercialized product — a bone graft extender and substitute — and two late-stage clinical programs focusing in engineering cartilage tissue for knee and back, respectively, the company is poised to capture an opportunistic yet untapped market. OneMedRadio spoke with CFO Scott Gill about market opportunity, and finding success in a notoriously unfriendly space.
Release: Actium Biosystems Appoints Distinguished Pharmaceutical Scientist Dr. Jessie L.-S. Au to its Scientific Advisory Board
Actium Cancer Treatment (ACT) platform’s controlled heat (hyperthermia) has the potential to substantially increase the efficacy of chemotherapy and radiation First application: non-muscle-invasive bladder cancer (NMIBC).
Atossa Genetics’ Portfolio Can Detect Breast Cancer. But Can These Products Eradicate It?
Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?